What you need to know about the coronavirus right now



Dec 14 (Reuters) - Here's what you need to know about the coronavirus right now:

Pfizer vaccine less effective against hospitalisation - study

Two doses of Pfizer-BioNTech's COVID-19 vaccine appear to have given 70% protection against hospitalisation in South Africa in recent weeks, according to a major real-world study which suggests weaker efficacy against the new Omicron variant.

The study said this compares with 93% efficacy against hospital admission during South Africa's outbreak of the Delta variant.

Pfizer on Tuesday said final analysis of its antiviral COVID-19 pill still showed near 90% efficacy in preventing hospitalisations and deaths in high-risk patients, and recent lab data suggests the drug retains its effectiveness against the Omicron variant.

Eli Lilly, Regeneron antibody therapies lose out against Omicron

German researchers have found that COVID-19 therapies developed by Eli Lilly and Regeneron lose most of their effectiveness when exposed in laboratory tests to the Omicron variant.

The group of Cologne and Berlin-based scientists found that protection from GlaxoSmithKline and Vir's antibody cocktail Xevudy held up when exposed to Omicron in a lab experiment but that this was not the case for Lilly's antibodies bamlanivimab and etesevimab and the antibodies in Regeneron's Ronapreve drug.

British PM Johnson faces rebellion in parliament

British Prime Minister Boris Johnson faces a large rebellion among his Conservative lawmakers on Tuesday in a parliamentary vote over new restrictions to try to curb the spread of the Omicron variant.

The measures, including ordering people to work from home, to wear masks in public places and use COVID-19 passes to enter venues, are expected to be approved by parliament but with Johnson relying on the opposition Labour Party for votes.

Omicron is showing a higher rate of reinfection than other variants and its growth rate is shortening in the United Kingdom, the Health Security Agency's chief medical adviser said on Tuesday.

Long queues formed at vaccine centres in England as hundreds of thousands of people rushed to get booster shots.

The chair of Britain's vaccine group said on Tuesday that calling an earlier and faster booster campaign would not necessarily have been the right policy given the scientific evidence at the time.

COVID-19 rattles major Chinese manufacturing province

Multiple companies have suspended operations in one of China's biggest and busiest manufacturing hubs as authorities double down to contain a COVID-19 outbreak, halting production of goods from batteries and clothing to textile dyes and plastics.

Zhejiang has reported 217 locally transmitted cases with confirmed symptoms in just eight days since the first case on Dec. 6. Prior to the current outbreak, it had reported just one local case this year.

Singapore mulls boosters requirement to qualify as 'fully' vaccinated

Singapore is considering requiring its residents to get a booster shot to qualify as fully vaccinated against COVID-19, its health minister said on Tuesday, as it seeks to protect its population from the Omicron variant.

The city-state of 5.5 million people currently allows only those counted as fully vaccinated - or recipients of two shots - to enter malls or dine in at restaurants or at hawker stalls.
Compiled by Linda Noakes, editing by Ed Osmond

免責聲明: XM Group提供線上交易平台的登入和執行服務,允許個人查看和/或使用網站所提供的內容,但不進行任何更改或擴展其服務和訪問權限,並受以下條款與條例約束:(i)條款與條例;(ii)風險提示;(iii)完全免責聲明。網站內部所提供的所有資訊,僅限於一般資訊用途。請注意,我們所有的線上交易平台內容並不構成,也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。

所有缐上交易平台所發佈的資料,僅適用於教育/資訊類用途,不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議,或是交易價格紀錄,或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。

本網站的所有XM和第三方所提供的内容,包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接,皆爲‘按原狀’,並作爲一般市場評論所提供,而非投資建議。請理解和接受,所有被歸類為投資研究範圍的相關内容,並非爲了促進投資研究獨立性,而根據法律要求所編寫,而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊,相關詳情請點擊 這裡查看。

我們運用 cookies 提供您最佳之網頁使用經驗。更改您的cookie 設定跟詳情。

風險提示:您的資金存在風險。槓桿商品並不適合所有客戶。請詳細閱讀我們的風險聲明